Interim results 1993.

A video explaining the 1993 interim results. There is a brief presentation of the key figures and then the chief executive, John Robb, outlines the different variables which have impacted on Wellcome's global performance. In the City, a fund manager, Steve Putnam, explains the reasons he would recommend the purchase of shares in a certain company. A pharmaceutical analyst, James Culverwell, also comments. An American analyst, Paul Brooke, talks about the potential for growth being capped in light of Hilary Clinton's review on drugs pricing in the US pharmaceutical industry. The analysts also foresee that competition from SmithKline will come with the development of a new anti-viral drug. An analyst explains why it is important for employees to care about the share price; to ensure shareholder confidence. The net results is that there will be pressure on internal costs with the suggestion that restructuring may occur.